Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors

Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors

Background: Immune checkpoint inhibitors (ICIs) have improved outcomes significantly for patients across multiple tumor types, and now are being used in combination with other therapies and in earlier settings where treatment intent is curative. Immune-related adverse events occur commonly and there...

Full description

Saved in:
Bibliographic Details
Main Authors: Abdulrahman Alghabban, MD, Lucy Corke, MD, Hans Katzberg, MD, Vera Bril, MD, Carolina Barnett-Tapia, MD, Warren Mason, MD, Raed Alothman, MD, Abdul Razak Albiruni Ryan, MD, David Hogg, MD, Srikala Sridhar, MD, Neesha Dhani, MD, Anna Spreafico, MD, Lawson Eng, MD, Adrian Sacher, MD, Penelope Bradbury, MD, Geoffrey Liu, MD, Natasha Leighl, MD, Frances A. Shepherd, MD
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:JTO Clinical and Research Reports
Subjects:
Myasthenia gravis
Immune checkpoint inhibitors
Immune-related neurotoxicity
Myositis-myocarditis overlap
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324001425
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666364324001425

Similar Items